Bromfenac

Generic Name: Bromfenac

Brand Names: Bromday, Bromsite, Prolensa, Xibrom, Yellox

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₂BrNO_₃

CAS Number: 91714-94-2

Unique Ingredient Identifier: 864P0921DW

Background: Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.

Indication: For the treatment of postoperative inflammation in patients who have undergone cataract extraction.

Associated Conditions: Eye Pain, Ocular Inflammation

Clinical Trials

Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery

Phase 4

Completed

Conditions: Cataract
Cystoid Macular Edema After Phacoemulsification

Interventions: Drug: Bromfenac
Drug: Moxifloxacin 0.5% ophthalmic solution
Drug: Dexamethasone phosphate 0.1%

First Posted Date: 2025-01-20

Last Posted Date: 2025-05-06

Lead Sponsor: Inas Abd

Target Recruit Count: 87

Registration Number: NCT06785090

Locations: 🇮🇶
College of Medicine, University of Baghdad, Baghdad, Baghdad Governorate, Iraq

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

Phase 4

Active, not recruiting

Conditions: Anterior Chamber Inflammation
Ocular Pain
Visual Outcome
Corneal Edema
Corneal Defect
Corneal Staining
CME - Cystoid Macular Edema

Interventions: Drug: Prednisolone Acetate 1% Oph Susp
Drug: Dextenza 0.4Mg Ophthalmic Insert
Drug: Prolensa 0.07% Ophthalmic Solution

First Posted Date: 2022-11-23

Last Posted Date: 2024-10-17

Lead Sponsor: Nicole Fram M.D.

Target Recruit Count: 50

Registration Number: NCT05626478

Locations: 🇺🇸
Advanced Vision Care, Los Angeles, California, United States

Effectiveness of Periocular Drug Injection in CATaract Surgery

Phase 3

Terminated

Conditions: Retinal Disease
Lens Diseases
Eye Diseases
Cystoid Macular Edema
Cataract
Macular Edema

Interventions: Drug: Bromfenac
Drug: Triamcinolone Acetonide
Drug: Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
Drug: Dexamethasone

First Posted Date: 2021-12-15

Last Posted Date: 2024-11-04

Lead Sponsor: Luigi Rondas

Target Recruit Count: 628

Registration Number: NCT05158699

Locations: 🇳🇱
Amphia, Breda, Netherlands
🇦🇹
Hospital of the Brothers of Saint John of God, Vienna, Austria
🇦🇹
Vienna Institute for Research in Ocular Surgery, Hanusch Krankenhaus, Vienna, Austria

and more 7 locations

Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy

Phase 2

Recruiting

Conditions: Familial Exudative Vitreoretinopathies

Interventions: Drug: Bromfenac Sodium

First Posted Date: 2021-11-04

Last Posted Date: 2023-11-22

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 39

Registration Number: NCT05107921

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms

Phase 1

Conditions: Presbyopia

Interventions: Drug: Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound

First Posted Date: 2021-08-16

Last Posted Date: 2021-08-17

Lead Sponsor: Optall Vision

Target Recruit Count: 11

Registration Number: NCT05006911

Locations: 🇲🇽
Optall Vision, Mexico City, Mexico

PCME Prevention in Patients With NPDR

Phase 4

Completed

Conditions: Cystoid Macular Edema Following Cataract Surgery

Interventions: Drug: Dexamethasone Ophthalmic
Drug: Placebo
Drug: Bromfenac Ophthalmic 0.09% Ophthalmic Solution
Procedure: Phacoemulsification surgery (PHACO)

First Posted Date: 2021-06-25

Last Posted Date: 2022-05-20

Lead Sponsor: Klinički Bolnički Centar Zagreb

Target Recruit Count: 90

Registration Number: NCT04940338

Locations: 🇭🇷
KBCZagreb, Zagreb, Grad Zagreb, Croatia

Control of Pain in Intravitreal Injections Using Topical NSAIDs

Phase 4

Completed

Conditions: IVI
Intravitreal Injections

Interventions: Drug: Bromfenac
Drug: Artificial tears

First Posted Date: 2020-04-13

Last Posted Date: 2023-06-12

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 46

Registration Number: NCT04343222

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Effect of Bromfenac on Pain Related to Pterygium Surgery

Phase 4

Completed

Conditions: Pterygium
Pain

Interventions: Drug: 0.1% bromfenac

First Posted Date: 2019-07-17

Last Posted Date: 2019-07-17

Lead Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University

Target Recruit Count: 60

Registration Number: NCT04022811

Locations: 🇨🇳
Zhongshan Opthalmic Center, Guangzhou, Guangdong, China
🇨🇳
Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China